Cohance Lifesciences Limited (NSE:COHANCE)

Cohance Lifesciences Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	473.7	1,792	4,873	3,003	4,113	4,538
Depreciation & Amortization	1,914	1,828	1,610	546	464.6	390.22
Other Amortization	45	45	57.6	-	-	3.91
Loss (Gain) From Sale of Assets	77.4	-16.2	0.2	0.7	0.07	-0.01
Loss (Gain) From Sale of Investments	-213.7	-12.2	-235.2	-449.1	-156.87	-82.03
Stock-Based Compensation	-18.2	-38.1	216.2	19.7	-	-
Provision & Write-off of Bad Debts	10.7	10.7	-	-	-	-
Other Operating Activities	-105	-134.2	218.2	8.5	93.58	389.52
Change in Accounts Receivable	1,275	1,025	-1,336	128.2	1,245	-1,361
Change in Inventory	-1,411	-945.8	1,408	816.1	-293.93	-823.37
Change in Accounts Payable	834.7	128.4	-78.8	-225.2	-357.99	232.04
Change in Other Net Operating Assets	-	-	-	-	-535.05	12.55
Operating Cash Flow	2,952	3,683	6,734	3,848	4,572	3,300
Operating Cash Flow Growth	42.15%	-45.30%	75.00%	-15.84%	38.54%	-13.74%

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-2,382	-2,199	-3,168	-518.8	-2,859	-751.87
Sale of Property, Plant & Equipment	281.3	205.2	1.4	-	0.72	0.01
Cash Acquisitions	-449.6	-	-7,280	-	-	-
Investment in Securities	1,381	-568.8	6,231	-3,101	844.55	-560.72
Other Investing Activities	98.1	16.7	318.2	-4.2	63.79	-48.8
Investing Cash Flow	-1,071	-2,546	-3,897	-3,624	-1,950	-1,361

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Long-Term Debt Issued	-	-	373.1	-	-	-
Total Debt Issued	472.4	-	373.1	-	-	-
Short-Term Debt Repaid	-	-12.1	-3,120	-270.4	-26.11	-385.66
Long-Term Debt Repaid	-	-1,123	-251.1	-60	-241.33	-98.58
Lease Payments	-212.3	-197.9	-140.3	-14.5	-3.75	-2.53
Total Debt Repaid	-676.1	-1,135	-3,371	-330.4	-267.43	-484.24
Net Debt Issued (Repaid)	-203.7	-1,135	-2,998	-330.4	-267.43	-484.24
Issuance of Common Stock	11	324.3	88	-	-	-
Common Dividends Paid	-	-	-	-	-2,037	-1,018
Other Financing Activities	-1,555	-841.1	-363.7	-69.5	-115.56	-62.31
Financing Cash Flow	-1,748	-1,652	-3,274	-399.9	-2,420	-1,565

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	27.3	38.9	20.8	-	-	0
Net Cash Flow	160.6	-475.1	-416.7	-175.7	202.39	373.82

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	570.6	1,484	3,566	3,329	1,713	2,548
Free Cash Flow Growth	-58.23%	-58.37%	7.11%	94.35%	-32.78%	-6.21%
Free Cash Flow Margin	2.77%	6.54%	13.67%	31.66%	12.78%	19.30%
Free Cash Flow Per Share	1.48	3.88	9.29	13.08	6.73	10.01
Levered Free Cash Flow	1,299	401.1	-3,380	2,967	1,079	1,027
Unlevered Free Cash Flow	1,508	633.85	-3,123	3,014	1,159	1,066
Free Cash Flow After Leases	358.3	1,287	3,425	3,314	1,709	2,546

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	341.1	341.1	363.7	69.5	115.56	62.31
Cash Income Tax Paid	677.7	677.7	1,759	1,100	1,458	1,843
Change in Working Capital	698.8	207.6	-7.3	719.1	57.68	-1,940

Data Source: S&P Global Market Intelligence Last updated: Nov 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 12, 2026

Data Sources Report a data error